NCT00149552

Zinc Therapy in HIV Infected Individuals Who Abuse Drugs

Zinc Therapy in Zinc Deficient HIV Positive Drug Users

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 231 (actual)
• Sponsor: Florida International University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Zinc deficiency is prevalent in HIV infected individuals who abuse drugs. The purpose of this study is to determine if zinc therapy will prevent immune failure in HIV infected individuals who abuse drugs and have low plasma zinc levels.

Detailed description

Low levels of zinc are associated with an increased risk of HIV-related death and opportunistic infections in HIV infected individuals. Drug users are especially susceptible to zinc deficiency. The purpose of this trial is to evaluate the effectiveness of zinc therapy in preventing immune failure in HIV infected individuals who abuse drugs. This trial will last 30 months. Participants will be randomly assigned to receive either zinc supplements or placebo. Male participants will receive 15 mg of zinc and female participants will receive 12 mg of zinc. Clinical and laboratory study visits will occur at 3 or 6 month intervals throughout the study.

Conditions

• HIV Infections
• Substance-Related Disorders

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	zinc	supplementation with zinc gluconate

Timeline

• Start date: 2001-06-01
• Completion: 2007-01-01
• First posted: 2005-09-08
• Last updated: 2012-03-05

Locations

1 site across 1 country: United States